Replimune Group, Inc. (NASDAQ:REPL) Receives $16.20 Consensus Target Price from Analysts

Shares of Replimune Group, Inc. (NASDAQ:REPL) have received an average recommendation of “Buy” from the six ratings firms that are covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $16.20.

Several research firms have recently commented on REPL. JPMorgan Chase & Co. decreased their price target on shares of Replimune Group from $17.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Roth Mkm initiated coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective on the stock. Roth Capital raised Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Barclays upped their price target on Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research note on Friday, June 7th. Finally, Wedbush reiterated an “outperform” rating and issued a $16.00 price objective on shares of Replimune Group in a research report on Thursday, June 6th.

Insider Activity at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction on Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the sale, the chief financial officer now directly owns 101,057 shares in the company, valued at $1,028,760.26. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Replimune Group news, insider Konstantinos Xynos sold 15,881 shares of the business’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $7.50, for a total value of $119,107.50. Following the completion of the transaction, the insider now directly owns 117,131 shares of the company’s stock, valued at $878,482.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $10.18, for a total value of $90,988.84. Following the completion of the sale, the chief financial officer now owns 101,057 shares of the company’s stock, valued at $1,028,760.26. The disclosure for this sale can be found here. Corporate insiders own 20.60% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Several institutional investors have recently modified their holdings of REPL. Price T Rowe Associates Inc. MD raised its holdings in Replimune Group by 12.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after buying an additional 699,679 shares during the period. Millennium Management LLC raised its holdings in shares of Replimune Group by 575.1% during the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after acquiring an additional 2,656,173 shares during the period. Vanguard Group Inc. lifted its position in Replimune Group by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock valued at $22,634,000 after acquiring an additional 32,555 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Replimune Group by 300.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock worth $18,874,000 after purchasing an additional 1,679,553 shares during the period. Finally, Rafferty Asset Management LLC increased its holdings in Replimune Group by 148.1% during the 4th quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock worth $3,906,000 after purchasing an additional 276,596 shares in the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Price Performance

NASDAQ:REPL opened at $10.44 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 13.46 and a quick ratio of 13.46. The stock has a market cap of $641.17 million, a P/E ratio of -3.22 and a beta of 1.22. The company has a fifty day moving average price of $9.82 and a 200 day moving average price of $8.24. Replimune Group has a one year low of $4.92 and a one year high of $20.42.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. Analysts anticipate that Replimune Group will post -3.13 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.